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Mitochondrial dysfunction arises from an inadequate number of mitochondria, an inability to 
provide necessary substrates to mitochondria, or a dysfunction in their electron transport and 
ATP-synthesis machinery. Occurrences of mitochondrial dysfunction are due to genetic or 
environmental changes in the mitochondria or in the nuclear DNA that codes mitochondrial 
components. Currently, drug options are available, yet no treatment existing in sight of this 
disease and needs a new insight into molecular and signalling pathways for this disease. 
MicroRNAs (miRNAs) are small, endogenous, non- coding RNAs functions as a master 
regulator of gene expression. The evolution of miRNAs in the last 2 decades emerged as a 
key regulator of gene expression that controls physiological, pathological, cellular, 
differentiation processes and metabolic homeostasis such as development and cancer. It has 
been known that miRNAs are a potential biomarker in both communicable and non 
communicable diseases. But, in the case of mitochondrial dysfunction in miRNAs the number 
of studies and investigations are comparatively less to other diseases and dysfunctions. In this 
review, we have elaborated the roles of miRNAs in the mitochondrial diseases and 
dysfunctions. 
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To sustain life and to support organ functions, our body requires more than 90% of the 
energy, which is possible through mitochondria “the power house of the cell”. Mitochondrial 
dysfunction arises from an inadequate number of mitochondria, an inability to provide 
necessary substrates to mitochondria, or a dysfunction in their electron transport and ATP-
synthesis machinery (Nicolson, 2014). Mitochondrial dysfunction has been correlated with 
metabolic diseases such as obesity; Diabetes mellitus type 1 and type 2 (Cheng and Almeida, 
2014), age related diseases and neurodegenerative diseases like Alzheimer’s disease, 
Parkinson’s disease (Grimm et al., 2016 ; Arun et al., 2016) cancer (Sotgia et al., 2011; 
Jezierska-Drutel et al., 2013) and majorly in cardiovascular diseases (Limongelli et al., 2012). 
MicroRNAs (miRNAs) are single stranded, small, non coding RNAs mainly transcribed as 
long primary transcripts in the nucleus and subsequently cleaved to form stem loop structured 
precursor molecules of 70 nt in length (pre- miRNAs) by Drosha (Panagal et al., 2018). The 
precursor stem loop structure is then transported to the cytoplasm; later they are acted upon 
an enzyme RNase III Dicer to produce 22 nt mature miRNAs (Panagal et al., 2018). 
Generally, mature miRNAs can identify their cognate mRNA and bind its 3’ end of the 
untranslated region (UTR) for the post-transcriptional repression activity (Panagal et al., 
2018; Panagal et al., 2018).  
There are a number of miRNAs that have been distinguished and characterized in human 
diseases (Wang et al., 2019). MiRNAs, which translocate into the mitochondria, are known as 
mitochondrial miRNA (mitomiR). It has been established that mitomiRs can regulate gene 
expression, report suggesting that after translocation, mitomiRs can bind to the 3’- end of a 
mitochondrial gene, altering its regulation. MicroRNAs perform as anti-regulators of gene 
expression (Giuliani et al., 2017). Interestingly, there are so many miRNAs that plays an 
important role in the mitochondrial diseases and dysfunctions for example miR-122, miR-
762, miR-217 etc (Wang et al., 2019; Yan et al., 2019., Tang et al., 2019). 
The evolution of miRNAs in the last 2 decades emerged as a key regulator of gene expression 
that controls physiological, pathological, cellular, differentiation processes and metabolic 
homeostasis (Sekar et al., 2019; Sekar et al., 2016). miRNAs are a potential biomarker in 
both communicable and non communicable diseases. But, in the case of mitochondrial 
dysfunction in miRNAs the number of studies and investigations are comparatively less to 
other diseases and dysfunctions. In this review, we have elaborated on the roles of microRNA 
in the mitochondrial diseases and dysfunctions. 
 
2. Relationship of miRNAs in mitochondrial diseases and dysfunctions 
It has been suggested that miRNAs are involved in many biological processes including 
proliferation, migration, invasion differentiation and apoptosis (Panagal et al., 2018; Panagal 
et al., 2018; Giuliani et al., 2017). Inspite of, miRNAs involved in several diseases and their 
role been clearly delineated (Sekar et al., 2019), up to our knowledge publications related to 
miRNAs in mitochondria and its related diseases is very less; we summarize below some of 
the research evidence from those published articles. 
Recently Giuliani A et al 2017  illustrated the role of miRNAs on mitochondria in 
senescence.  In that article, they explained miR-146 was translocated into mitochondria and 
alter the energetic, oxidative and inflammatory status of senescent cells, suggesting that 
miRNA-146 is involved in aging induced inflammation thereby reduce the aging rate and 
postpone the development of age- related disorders (Giuliani et al., 2017).  
It has been reported that the mitochondrial deacetylase sirtuin 3 (SIRT 3) plays a major role 
in the maintenance of mitochondrial function by regulating the mitochondrial acetylome in 
myocardial issues. On the other hand, several miRNAs has been associated with cardiac 
remodelling by modulating key signalling elements in the myocardium. In particular, miR-
195 has been identified as a molecule that down regulates the SIRT 3 expression by directly 
targeting its 3’ UTR and alters the cardiac energy metabolism through elevated PDH 
acetylation levels and raised ATP synthase (Zhang et al., 2018). 
A study by Koh E H, et al 2016 has reported on mitochondrial activity in human white 
adipocytes is regulated by the ubiquitin carrier protein 9/ microRNA- 30a axis. UBC-9 and 
miRNA- 30a exhibit an inverse expression in adipose tissue, and miRNA-30a robustly 
elevated in brown fat only. Depletion of UBC-9 by SiRNA of miRNA-30a mimics in human 
white adipocytes, reflected features of brown fat cells. Their results showed that UBC-9 
depletion induced a brown fat gene program in human subcutaneous adipocytes suggesting 
that browning effect protects against obesity induced metabolic diseases in humans and 
animal models of type 2 diabetes (Koh et al., 2016). 
Wu Q et al 2017 reported that the expression of miRNA-1224-5p mediates mitochondria 
damage in lung tissues of silica- induced pulmonary fibrosis and fibroblasts exposed to TGF-
ß1. Suppression of miR-1224-5p hampers the progression of silica- induced fibrosis in vivo 
and TGF-ß1- induced myofibroblast differentiation in vitro (Wu et al., 2017). 
Rippo et al 2014 worked on endothelial cells, a well established model of replicative 
senescence, where the results revealed that miRNA-146a, miRNA- 34a and miRNA- 181a are 
up regulated  and conversely their target Bcl-2 being down- regulated. Interestingly, Bcl-2 an 
anti- oxidant, anti- apoptotic factor that regulates mitochondrial fission/ fusion and autophagy 
critically involved in maintaining mitochondrial integrity, plays an important role by 
controlling the mitochondrial function and dysfunction during cellular aging. Their report 
concluded that aging related mitochondrial microRNAs may play a regulatory role by 
regulating mitochondrial protein expressions (Rippo et al., 2014). Figure 1 shows the role of 
microRNA in mitochondria function/dysfunction. 
Another miRNA, miR- 145 has been attributed in regulating mitochondrial apoptotic pathway 
in the heart challenged with oxidative stress. It is hypothesised that miR- 145 may represent a 
potential therapeutic target for treating oxidative stress- associated with cardiovascular 
disease such as myocardial ischemia/ reperfusion injury (Li et al., 2012).  
A Recent report stated that non coding RNAs such as miRNA act as a responsible gene 
regulator and has been involved in cellular signalling pathways. Yan K, et al 2019 reported 
on miR-762, a new miRNA in the mitochondrial dysfunction. miR-762 predominantly 
translocated in the mitochondria and was significantly upregulated upon anoxia / 
reoxygenation (A/R) treatment. Knockdown of endogenous miR-762 considerably attenuated 
the decrease in intracellular ATP levels, increased in reactive oxygen species- ROS levels, 
the decreased in mitochondrial complex I enzyme activity and the increase in apoptotic cell 
death in cardiomyocetes which was induced by A/R treatment. Enforced expression of miR– 
762 dramatically decreased the protein levels of endogenous NADH dehydrogenase subunit 2 
(ND 2) but had no effect on the transcript level of ND2. Inhibitory effect of miR- 762 
downregulation was attenuated by ND2 knockdown concluding that miR- 762 may yield a 
fresh therapeutic target for myocardial infarction (Yan et al., 2019).  
Dahlmans D, et al 2017 has mentioned about decreased mitochondrial function playing an 
important role in numerous pathologies including cardiomyopathy, cancer, neuro- muscular 
degeneration, Alzheimer’s disease and type-2 diabetes mellitus (T2DM). A diminished 
mitochondrial oxidative capacity in skeletal muscle tissue has frequently been reported in 
humans with T2DM and insulin resistance. They also revealed that miR- 199a and miR-214 
has been upregulated during myocardial hypoxia and elevated in cardiac biopsies of heart 
failure patients and actively repress the PPARδ a well- known transcription factor in the 
regulation of mitochondrial metabolism. Interestingly from a therapeutic standpoint, in vivo 
silencing of miRNAs with specific antogomirs resulted in a restoration of PPARδ levels, 
normalization of mitochondrial fatty acid oxidation and rescue of cardiac failure. In addition, 
they quantified the expression of miRNAs in skeletal muscle biopsies of endurance – trained 
athletes, lean and obese, sedentary subjects, type 2 diabetic patients and found that the 
expression of validated miRNAs showed a strong relationship with in vivo mitochondrial 
function in humans (Dahlmans et al., 2017).  
A research article by Galvan M et al 2017 on miR- 93, a hallmark miRNA in diabetic 
environment has been shown to be downregulated in diabetes mellitus. Additionally, they 
also illustrated on miR-21 a well known miRNA known to be upregulated in patients with a 
variety of kidney diseases and in animal models of chronic kidney disease. They concluded 
that mice lacking miR-21 were guarded against kidney fibrosis enhancing through 
mitochondrial fatty acid oxidation and targeting of peroxisome proliferator activated receptor 
(α PPAR) (Galvan et al., 2017). 
Interestingly, a study by Wen F et al 2018 on resistin levels which is associated with 
steatohepatitis and non- alcoholic fatty liver disease confirmed that miR-34a has been 
upregulated by resistin and mediated by CCAAT/enhancer-binding protein beta (C/EBPß). 
Furthermore, miR-34a inhibit the PPAR α signaling pathway by binding to sites in the 3’ 
UTR of adipoR2 genes and also involved in the 5’- adenosine monophosphate- activated 
protein kinase (AMPK) pathway in mitochondria (Wen et al., 2018).  
Li K et al 2016, in their study showed a remarkable upregulation of miR- 144-3p with 
increased expression of key genes involved in maintaining the mitochondrial function, 
including peroxisome proliferator- activated receptor γ coactivator -1α (PGC-1α), nuclear 
respiratory factor 1 (NRF-1) and mitochondrial transcription factor A (TFAM). In The same 
cells,  miR- 144-3p overexpression significantly inhibited the protein expression of ß- 
amyloid precursor protein (APP). In the same study, noticeable raise in cellular ATP, cell 
viability and the relative copy number of mitochondrial DNA (mtDNA) was noted, 
3uggesténg that miR-144-3p plays an important role in maintaining mitochondrial function, 
along with its target gene APP (Li et al., 2016).  
Interestingly, Liu et al 2018 reported that miR- 138 mimic promoted the proliferation and 
mitochondrial membrane potential (MMP) levels in human pulmonary artery smooth muscle 
cells (HPASMCs) suggesting that miR-138 promote proliferation and suppress mitochondrial 
depolarization of HPASMCs by targeting TASK-1gene (Liu et al., 2018).  
Wang L, et al 2014 identified a microRNA that targets Glutathiïne peroxidise- 1 an important 
intracellular antioxidant enzyme that enzymatically quench hydrogen peroxide to water and 
limit its harmful enfects (GPx 1) and maintain redox homeostasis. They used quantitative 
real- time PCR (qPCR) which demonstrated the markedly upregulated expression of miR- 
181a in H2O2- treated H9C2 cells and the down regulation of miR-181a correlated with 
inhibition of H2O2 induced cellulav apoptosis, ROS production and increase in 
melondialdehyde 
(O
                                                                                                                                                       
A) levels. Their results suggested that miR- 181a plays an important role in regulating the 
mitochondrial apoptotic pathway in cardiomyocytes provoked by oxidative stress and also it 
is considered as a potential therapeutic target for the treatment nf oxidative stress- associated 
cardiovascular diseases (Wang et al., 2014). Figure 2 shows the microRNA regulation on 
mitochondrial apoptotic pathway. 
An interesting spudy by Jeong H J et al 2013"elaborated on mitochonlrial dysfunction by 
impairment of insulin signalling in SK- Hep 1 cells via a reduction in the expression of IRS- 
1 3’ UTR. Uskng a reporter gene assay they confirmed that miR-96 authentically targeted 
IRS- 1 gene 3’ UTR and also the ectopic expression of miR- 96 caused a substantial decrease 
in ITR- 1 protein expression and a consequent impairment in insulin signalling. They 
suggested that upregulation of miR- 96 by mitochondrial dysfunction contributes to the 
development of insulin resistance by targeting IRS- 1 in SK- Hep 1 cells (Jeong et al., 2013).  
The research article by Jiang L et al 2013 found that mitochondrial uncoupling protein 2 
(UCP2) was induced in$kidney tubular epithelial cells. In NRK- 52E cells, TGF- ß 1 
remarkably induced UCP- 2 expression and the knockdown of UCP 2 mRNA largely 
abolished the effect of TGF- ß 1. Moreover, they found that the UCP 2 mRNA is a direct 
target of miR- 30e. Conversely, miR- 30e mimics significantly inhibit the TGF- ß 1, whereas 
miR- 30e inhibitor imitates TGF- ß 1 effect on the NRK-52E cells. Thus, they conclude that  
the mitochondrial miR- 30/UCP2 axis has an important role in mediating TGF- ß 1- induced 
epithelial- mesenchymal transition and kidney fibrosis. Targeting this pathway may shed new 
light for the future of fibrotic kidney disease therapy (Jiang et al., 2013). 
Thus from the above discussed studies, one can see the correlation between several miRNAs 
and mitochond2ia in various diseases and disorders. Moreover, the miRNA seems to have a 
pivotal role in initiation and progression of various pathologies mediated by!affecting 
mitochondrial functions. Some MiRNAs upregulation seems to exert a beneficial role via 
mitochondrial intervention in reversing the pathogenesis and protection against various 
metabolic conditions. From a therapeutic viewpoint, these miRNAs and their mimics show a 
promising ftture and opens new avenues in diseases managements and prognosis through 
mitochondrial energy dependent pathways. However, there is a huge lacuna on deciphering 
the exact role of those"miRNAs on mitochondria mediated pathogenesis and alleviatory 
effects. Hence there is a need for future functional studies in this emerging discipline.  
3. Clinical Perspective and Future directions 
MicroRNAs (miRNAs) are believed to be the most important dictatorial molecules in the 
cells and controlling broad variety of cellular functions such as proliferation, migration 
invasion and apoptosis (Sekar et al., 2016, Bai et al., 2019). miRNAs interact with the 
messenger RNAs (mRNAs) at the post transcriptional levels and regulate the gene 
expressions by either repression or degradation of the translation mechanisms. In general 
miRNAs considered being a key regulator for breast cancer progressions and readily detected 
in all kinds of body fluids including serum, blood, urine, semen, etc (Li et al., 2019, 
Humphries et al., 2019). In this perspective, understanding the role of miRNAs in 
mitochondria is significant and it may open the gateway for the discovery or the identification 
of new prognostic, diagnostic or therapeutic targets for mitochondrial dysfunction or its 
related diseases. Interestingly, many articles show that potential impact of miRNAs as a 
biomarker for mitochondrial dysfunction and their interaction with surrounding molecular 
pathways (Li et al., 2016; Liu et al., 2018; Wang et al., 2014; Jeong et al., 2013; Jiang et al., 
2013).  
miRNAs that are present in the mitochondrial fraction and alters the mitochondrial function 
are called MitomiR (Srinivasan et al., 2015) . Among the reported miRNAs, miR-1291, miR-
138, miR-150, miR-199a-3p, and miR-532-5p are involved to modify the expression of key 
glycolytic enzymes, including glucose transporters (GLUTs) suggesting that mitochondrial 
glucose uptake can be modified by MitomiR (Srinivasan et al., 2015). The mitochondrial 
fission and fusion machinery is very important to eliminate unwanted mitochondrial fraction 
from the cells (Wang et al., 2011). Interestingly, mitochondrial fission 1 protein (Fis1) is 
targeted by miR-484, since Fis1 is considered as a necessary protein for mitochondrial fission 
and apoptosis (Wang et al., 2011). So mitomiR plays an important role in the mitochondrial 
dysfunctions by targeting various proteins and signalling pathways that are essential for 
regular mitochondrial function.  
A review of Tomasetti M, et al 2014 illustrated that the modulation of miRNAs levels may 
provide a new therapeutic approach for the treatment of mitochondrial- related pathologies, 
including neoplastic diseases (Tomasetti et al., 2014). Interestingly, Kato M, et al 2013 
described the role of miRNAs in the pathobiology of various diabetic complications and their 
involvement in oxidative stress. They revealed the potential use of differentially expressing 
miRNAs as novel diagnostic biomarkers and therapeutic targets, suggesting that miRNAs act 
as a potential mediator and biomarker of diabetic complications (Kato et al., 2013).  
Recent research suggested that miRNAs are potential biomarker in both communicable and 
non communicable diseases (Sekar et al., 2016; Bai et al., 2019; Li et al., 2019; Humphries et 
al., 2019), On the other hand, in the case of mitochondrial dysfunction in miRNAs the 
number of studies and investigations are comparatively less to other diseases and 
dysfunctions. We still require more research to prove that miRNAs are vibrant prognostic, 
diagnostic and therapeutic biomarker for mitochondrial dysfunction. Surprisingly, Tomasetti 
M, et al 2014 summarizes the role of miR- 126 in the malignant mesothelioma (MM) H28 
cell lines affect the mitochondrial energy metabolism, reduced mitochondrial respiration and 
promote the glycolysis. Furthermore, the above parameters resulted in suppression of MM 
tumour and miR-126 may act as therapeutic options for fatal neoplastic disease (Humphries 
et al., 2019). Another study by Choic DC et al 2014 also summarized on downregulation of 
relA , a component of NF- κB assosciated with miR-7. Their findings showed suppression in 
the nuclear factor-κB (NF-κB) rather than activation in the pathogenesis of Parkinson disease 
by miR-7(Choi et al., 2014). Table 1 shows the differentially expressed miRNAs involved in 
mitochondrial pathways. At present there are many therapeutic strategies that are available. 
Inhibition of oncogenic miRNAs by antisense RNA and miRNAs mimics or viral encodeced 
overexpression of tumour suppressor miRNAs (Sekar et al., 2016; Bai et al., 2019) are 
examples of the above said therapeutic strategy, but still we need to have future validation by 
high throughput preclinical and clinical studies . 
4. Conclusion  
In general, we conclude that several miRNAs including miR-34a, miR- 145, miR- 146, miR- 
176, miR -181a, miR -762, miR -199a, miR-214, miR-93, miR- 96 play a vital role in many 
disease progressions or suppressions. The available evidences suggest a new framework for 
considering and understanding MitomiR as a novel biomarker in the mitochondrial 
dysfunctions linking it with many complex diseases. Mitochondrial dysfunction is also 
attributed to post transcriptional modifications of targeted gene expressions in non- 
communicable diseases including cardio vascular and neurodegenerative disorders. We 
already know the concept of miRNAs as biomarkers for various diseases which was explored 
thoroughly, but further, the analysis of miRNA profiles in serum, plasma and blood cells 
linked with development and progression of mitochondrial dysfunctions may lead to novel 
therapeutic strategies. In addition, miRNAs may serve as a potential prognostic and 
diagnostic marker for mitochondrial linked diseases. Still, significant research endeavours has 
to be exercised on miRNAs that will determine the future use and clinical application. 
Nevertheless, the applicability of miRNAs in mitochondrial research remains elusive. The 
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